Table 2

Response and follow-up of gouty arthritis patients receiving anakinra.

Follow-up characteristics

Anakinra for ≤3 days

Number = 23

Anakinra for >3 days

Number = 17


Response to anakinra, number (%)

Good

20 (87%)

16 (94%)

Partial

2 (9%)

0 (0%)

No response

1 (4%)

1 (6%)

Follow-up duration, months, median (IQR)

6.0 (1.5 to 14.0)

8.0 (3.0 to 13.0)

Prevention of relapse, number (%)

Total

17 (74%)a

13 (76%)

Low-dose colchicine

16 (89%)

7 (54%)

NSAIDs

3 (17%)

1 (8%)

Steroids

1 (6%)

2 (15%)

Anakinra

1 (6%)

9 (69%)

Relapse, number (%)

6 (26%)

7 (41%)

Delay to relapse, days, median (IQR)

15.0 (6.0 to 26.3)

60.0 (12.5 to 125.0)

Skin reaction

None

None

Infectious events under anakinra therapy (delay after starting anakinra)

H1N1 infection (1 day)

Staphylococcus aureus tophus (1 year)

S. aureus tophus (4 years)

S. aureus lung abcess (1 month)

Erysipela of the leg (2 months)

Streptococcus B urinary tract infection (1 month)

S. aureus knee arthritis (1 year)


aSome patients also had different treatment. IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs.

Ottaviani et al. Arthritis Research & Therapy 2013 15:R123   doi:10.1186/ar4303

Open Data